Recent Updates
Recently added Catalysts
LAB Neutral Sentiment

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Key Takeaway: Standard BioTools Inc. has announced that it will report its first quarter 2025 financial results on May 6, 2025. Following the report, the company will host a conference call at 4:30 p.m. ET to discuss its financial performance and operational advancements. Investors can access the call via a dedicated phone line or through a live webcast on the company's Investor Relations page.
Price reaction · baseline $1.19 (2025-04-21 close) · hit after-hours · 1 other LAB headline(s) in the window, move may be shared
day 0 close · peak
+6.7%
day 1
+4.2%
day 3
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Standard BioTools is set to report its Q1 2025 financial results, indicating active business operations.
  • The company continues to support biomedical research with valuable technologies.
  • The upcoming conference call allows investors to gain insights into the company's performance and future plans.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Individuals can access the conference call by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Frequently Asked Questions

When will Standard BioTools report its Q1 2025 financial results?

Standard BioTools will report its Q1 2025 financial results on May 6, 2025.

How can I access the Standard BioTools conference call?

US callers can dial (888) 346-3970, while international callers should use (412) 902-4297.

What time will the conference call start on May 6, 2025?

The conference call will start at 4:30 p.m. ET on May 6, 2025.

Where can I find the archived webcast of the conference call?

The archived webcast will be available on the Investor Relations page of the company’s website.

What technologies does Standard BioTools provide?

Standard BioTools offers technologies like SomaScan, mass cytometry, and microfluidics.

Last updated: Apr 22, 2025